Literature DB >> 32761460

Retinal pigment epithelial characteristics in eyes with neovascular age-related macular degeneration : Long-term retinal changes under anti-vascular endothelial growth factor treatment.

Christian Ebner1,2, Clara Wernigg1,2, Christopher Schütze1,2, Birgit Weingessel1,2, Pia-Veronika Vécsei-Marlovits3,4.   

Abstract

PURPOSE: The aim of this study was to assess retinal pigment epithelial (RPE) and retinal structural changes in eyes with neovascular age-related macular degeneration (AMD) treated with anti-vascular endothelial growth factor (anti-VEGF) during long-term follow-up and to evaluate morphological markers potentially influencing prognosis.
METHODS: A total of 18 eyes of 18 patients with neovascular AMD were examined subsequent to completion of the Avastin Versus Lucentis in Age Related Macular Degeneration (MANTA) study following a mean period of 84 months (range 69-93 months). After receiving a loading dose of 3 intravitreal anti-VEGF injections subsequent to baseline of the MANTA study, patients were treated as needed (pro re nata, PRN). Functional and morphological changes were assessed, the latter using spectral domain optical coherence tomography (SD-OCT).
RESULTS: Retinal/RPE atrophy generally increased significantly during follow-up compared to baseline (fibrosis 28% vs. 89%, p = 0.0001, geographic atrophy, GA 0% vs. 67%, p = 0.0002, RPE porosity 61% vs. 100%, p = 0.009) whereas regenerative alterations tendentially increased until 3 months and then subsequently declined until the last visit (RPE thickening 28% vs. 11%, p = 0.22 and intraretinal hyperreflective foci 89% vs. 78%, p = 0.39).
CONCLUSION: Atrophic alterations of the retina and RPE are progressive and may partly be induced by anti-VEGF. Morphological findings may aid in the identification of prognostic markers in the progression of neovascular AMD. This could lead to a more targeted education of affected patients.

Entities:  

Keywords:  Bevacizumab; Hyperreflective intraretinal foci; Ranibizumab; Retina; Spectral domain optical coherence tomography

Year:  2020        PMID: 32761460     DOI: 10.1007/s00508-020-01718-6

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  2 in total

1.  Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study.

Authors:  Adnan Tufail; Praveen J Patel; Catherine Egan; Philip Hykin; Lyndon da Cruz; Zdenek Gregor; Jonathan Dowler; Mohammed A Majid; Clare Bailey; Quresh Mohamed; Robert Johnston; Catey Bunce; Wen Xing
Journal:  BMJ       Date:  2010-06-09

2.  Functional recovery of retinal pigment epithelial damage in experimental retinal detachment.

Authors:  S Tsuboi; J E Pederson; C B Toris
Journal:  Invest Ophthalmol Vis Sci       Date:  1987-11       Impact factor: 4.799

  2 in total
  1 in total

Review 1.  Significance of Hyperreflective Foci as an Optical Coherence Tomography Biomarker in Retinal Diseases: Characterization and Clinical Implications.

Authors:  Serena Fragiotta; Solmaz Abdolrahimzadeh; Rosa Dolz-Marco; Yoichi Sakurada; Orly Gal-Or; Gianluca Scuderi
Journal:  J Ophthalmol       Date:  2021-12-17       Impact factor: 1.909

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.